JPH025732B2 - - Google Patents

Info

Publication number
JPH025732B2
JPH025732B2 JP55501307A JP50130780A JPH025732B2 JP H025732 B2 JPH025732 B2 JP H025732B2 JP 55501307 A JP55501307 A JP 55501307A JP 50130780 A JP50130780 A JP 50130780A JP H025732 B2 JPH025732 B2 JP H025732B2
Authority
JP
Japan
Prior art keywords
glycine
threonine
brain
spinal cord
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP55501307A
Other languages
English (en)
Japanese (ja)
Other versions
JPS56500539A (https=
Inventor
Richaado Jei Waatoman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JPS56500539A publication Critical patent/JPS56500539A/ja
Publication of JPH025732B2 publication Critical patent/JPH025732B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP55501307A 1979-05-07 1980-05-06 Expired - Lifetime JPH025732B2 (https=)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/036,925 US4397866A (en) 1979-05-07 1979-05-07 Process for increasing glycine levels in the brain and spinal cord

Publications (2)

Publication Number Publication Date
JPS56500539A JPS56500539A (https=) 1981-04-23
JPH025732B2 true JPH025732B2 (https=) 1990-02-05

Family

ID=21891439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP55501307A Expired - Lifetime JPH025732B2 (https=) 1979-05-07 1980-05-06

Country Status (4)

Country Link
US (1) US4397866A (https=)
EP (1) EP0028257B1 (https=)
JP (1) JPH025732B2 (https=)
WO (1) WO1980002372A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362745A (en) * 1980-11-19 1982-12-07 Johnston Frederick B Medical process and preparation
ATE45672T1 (de) * 1983-05-16 1989-09-15 Massachusetts Inst Technology Eine pharmazeutische zusammensetzung zum zweck der behandlung einer neurologischen krankheit oder des alterns.
LU84891A1 (fr) * 1983-06-30 1985-03-29 Continental Pharma Derives de l'acide 2-aminoacetique,leur preparation et utilisation ainsi que compositions pharmaceutiques contenant ces derives
US5798371A (en) * 1995-01-13 1998-08-25 Komissarova; Irina Alexeevna Pharmaceutical composition endowed with an antialcoholic and nootropic effect
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
AUPR625901A0 (en) * 2001-07-10 2001-08-02 Mcgregor, Neil A method for treatment and/or prophylaxis
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
EP1490073A4 (en) * 2002-03-21 2006-02-01 Martin C Hinz SEGMENT OPTIMIZATION TECHNOLOGY FOR THE SEROTONIN AND CATECHOLAMINE SYSTEM
WO2004075724A2 (en) * 2003-02-21 2004-09-10 Hinz Martin C Serotonin and catecholamine system segment optimization technology
JP4638685B2 (ja) * 2003-06-10 2011-02-23 ハイデルベルガー ドルツクマシーネン アクチエンゲゼルシヤフト オフセット印刷機による印刷の際に湿し水を調量する方法
JP4913410B2 (ja) * 2004-01-14 2012-04-11 味の素株式会社 グリシンを含有する食品およびその用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6089M (https=) * 1967-01-11 1968-06-04
FR6088M (https=) * 1967-01-11 1968-06-04
FR6538M (https=) * 1967-02-13 1968-12-16
FR2081583A1 (en) * 1970-03-24 1971-12-10 Roberti Andre Threonine proto-glutamate - as hepatoprotective agent

Also Published As

Publication number Publication date
US4397866A (en) 1983-08-09
JPS56500539A (https=) 1981-04-23
WO1980002372A1 (en) 1980-11-13
EP0028257B1 (en) 1986-10-01
EP0028257A1 (en) 1981-05-13
EP0028257A4 (en) 1981-09-11

Similar Documents

Publication Publication Date Title
AU2025204612A1 (en) MDMA enantiomers
JPH025732B2 (https=)
CN101822676A (zh) 治疗运动疾病患者的方法
JP2000514420A (ja) 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ―２５２ａ誘導体の使用
Stocchi The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease
Smith et al. Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets
ZA200700395B (en) Novel formulation for L-tryptophane comprising carbidopa/benserazide
MXPA00012808A (es) El uso de analogo de acido valproico para tratamiento y prevencion de migrana y enfermedad afectiva.
EP3818981B1 (en) Synergic pharmaceutical composition of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain
US4435424A (en) Process for improving vigor and mood in normal human patients
KR20040028758A (ko) Ｇｖｇ를 사용하는 강박성 장애(ｏｃｄ) 및 ｏｃｄ-관련장애에 대한 신규의 치료
US4405629A (en) Process for increasing glycine levels in the brain and spinal cord
CA2382548C (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
CA1248454A (en) Cytidyl diphosphocholine-drug composition and process
CA2320556A1 (en) N,n-dichlorinated omega amino acids and uses thereof
US4624852A (en) Process and composition for treating neurological disorders and aging
EP0217258B1 (en) The use of choline or choline releasing compounds for reducing the perception of fatigue
US4775665A (en) Method and composition for treating neurological disorders and aging
US12329774B2 (en) Method and composition for enhancing the quality and benefits of sleep
US4737489A (en) Method and composition for treating neurological disorders and aging
FR3077201A1 (fr) Derives aminoacides contenant un groupement disulfanyle sous forme d'un inhibiteur de nep et d'apn pour la prevention et le traitement des douleurs relatives au nerf trijumeau
JP5127092B2 (ja) 小脳機能障害を予防および治療するための２−アミノ−６−トリフルオロメトキシ−ベンゾチアゾールの使用
CA1228301A (en) Method and composition for treating neurological disorders and aging
WO2023156275A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
JPH0645539B2 (ja) 鎮痛剤